| Sep 30 |
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
|
| Sep 30 |
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
| Sep 27 |
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
|
| Sep 17 |
BridgeBio achondroplasia asset infigratinib nabs FDA Breakthrough Therapy status
|
| Sep 17 |
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
|
| Sep 12 |
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
|
| Sep 11 |
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
|
| Sep 11 |
BridgeBio stock slides on discontinuation of CAH gene therapy
|
| Sep 11 |
BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine
|
| Sep 10 |
BridgeBio gets FDA RMAT status for Canavan disease gene therapy
|
